Moleculin Biotech Published Cardiac Safety Findings
A new peer-reviewed analysis suggests the drug Annamycin shows no evidence of dose-dependent cardiotoxicity.
Live Poll
Does evidence of improved safety in drug trials increase your trust in new medical treatments?